Given the clinical development of BPX-01 for the treatment of acne and the similarities between acne and rosacea, BioPharmX is also pursuing development of its lead product candidate in the indication for rosacea. We are currently evaluating BPX-01 in an open-label study consisting of up to 20 subjects with moderate-to-severe papulopustular rosacea. The study uses a 12-week once-daily treatment using BPX-01 1% minocycline.
Based on results from a four-week tolerability assessment, the company will evaluate moving forward into a phase 2/3 pivotal study in this indication. The phase 2/3 study will evaluate the safety and efficacy of BPX-01 for the treatment of moderate-to-severe papulopustular rosacea.
ROSACEA – The National Rosacea Society describes rosacea as a common, but poorly understood disorder of the facial skin that affects an estimated 16 million Americans, many of whom do not even know they have the condition. Rosacea is characterized by facial redness, pimples, bumpy breakouts, and thickening of the skin. The condition can also affect the eyes by causing dry eyes and blurred vision.